Ovid Therapeutics (OVID) Earnings Analysis

Ovid Therapeutics (OVID) next reports earnings on 2026-08-12, consensus EPS -0.1 USD. Last quarter (2026-03-18) it beat with EPS 0.06 USD vs -0.1 USD est (+160%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -6.88.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does OVID next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.1 USD
Revenue estimate0.00B

OVID earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-180.06 USD-0.1 USD+160%Beat
2025-08-13-0.06 USD-0.16 USD+62.5%Beat
2025-03-11-0.13 USD-0.16 USD+18.8%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

OVID valuation and analyst view

Trailing P/E-6.88
Trailing EPS-0.32775 USD
Price / book0.89
Dividend yield0.00%
Market cap0.31B
Analyst consensusBuy (11 buy / 3 hold / 0 sell)
Avg price target7 USD

Related research pages

Frequently asked questions

When is Ovid Therapeutics (OVID)'s next earnings date?

Ovid Therapeutics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.1 USD and revenue estimate of 0.00B.

Did OVID beat earnings last quarter?

In its 2026-03-18 report, OVID posted EPS of 0.06 USD versus a -0.1 USD estimate — a beat of 160%.

What is OVID's earnings track record?

Over the last 3 reported quarters with consensus data, OVID beat estimates 3 times (100%).

What is OVID's current P/E ratio and EPS?

OVID trades at a trailing P/E of -6.88 on trailing EPS of -0.327752103915712 USD.

What do analysts rate OVID?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 7 USD.